Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

Pronounced “soh-TIK-too,” SOTYKTU is a once-daily pill for adults with moderate to severe plaque psoriasis that works inside ...

See the full release here ... 432 adults and adolescents aged 12 years and older with plaque psoriasis affecting the scalp and body, across 49 sites in the United States and Canada.

1 Gooderham, M.J. et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that ...

BE SURE enrolled 478 participants with chronic plaque psoriasis for at least six months prior to screening and with an affected body surface ... clinical studies. The full BE SURE results will ...

Despite Humira's patent expiry, AbbVie successfully transitioned to new revenue sources, has upgraded its full-year EPS estimates ... is now approved to treat plaque psoriasis, psoriatic arthritis ...

The dosing interval for ixekizumab may be extended in some patients with plaque psoriasis, and switching between biologics ...

Roflumilast foam, 0.3% (Zoryve) used once-daily significantly improved itch and other symptoms of plaque psoriasis of the scalp and body, the phase III ARRECTOR trial showed.

Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...